Diclofenac Epolamine (Topical NSAID) and Asthma: Risk Assessment and Precautions

Diclofenac epolamine (topical NSAID patch/gel) carries a lower systemic exposure than oral diclofenac, but can still trigger bronchospasm in aspirin-exacerbated respiratory disease (AERD)—the triad of asthma, chronic rhinosinusitis with nasal polyps, and NSAID sensitivity.

Risk Stratification

Patient Profile	Risk Level	Recommendation
Asthma + nasal polyps + prior NSAID reaction (AERD)	High	Avoid all NSAIDs (oral & topical). Use acetaminophen, topical capsaicin, lidocaine.
Asthma + nasal polyps (no known NSAID reaction)	Moderate	Use with extreme caution; first dose under observation; have rescue inhaler.
Asthma alone (no polyps, no prior reaction)	Low	Generally safe; monitor for cough/wheeze.
Chronic urticaria/angioedema	Moderate-High	NSAIDs can exacerbate; avoid if possible.

Practical Guidance

• Consult physician before use if any asthma history.
• Lowest effective dose, shortest duration.
• Apply to intact skin only (avoids higher absorption).
• Monitor for: Wheezing, chest tightness, cough, nasal congestion, urticaria—discontinue immediately if occur.
• Alternatives: Topical non-NSAID (lidocaine, menthol, capsaicin), acetaminophen, physical therapy, joint injection.

Topical NSAIDs are not risk-free in AERD. Shared decision-making with a clinician aware of the patient's respiratory phenotype is essential.